National
HRC announces independent review of president ensnared in N.Y. AG report
Chicago-based law firm to undertake 30-day investigation
The nation’s leading LGBTQ advocacy group has announced to staff an independent review of Alphonso David, president of the Human Rights Campaign, after he was ensnared in the damning report from the New York attorney general finding Gov. Andrew Cuomo violated the law by sexually harassing 11 women employees.
A pair of emails — one from the Human Rights Campaign board, the other from David — went out Monday morning and announced the independent review would be conducted by the Chicago-based Sidney Austin LLP that will take no longer than 30 days to complete. The emails were shared with the Washington Blade and a representative for the Human Rights Campaign confirmed the emails were accurate.
David, in his email, says he “fully endorse[s]” the review, reiterating he has joined calls for Cuomo to resign and denies any wrongdoing.
“One thing this horrible situation reminds us of is that discrimination, misconduct and abuse often thrive in darkness, and it makes me more determined than ever to continue fighting injustice and speaking up for those who need our voice,” David writes.
A spokesperson from Sidney Austin LLP didn’t immediately respond in time for this posting to comment on the nature of the review, who will conduct it or the timeline to reach benchmarks within that 30-day window.
The announcement comes nearly a week after New York Attorney General Letitia James issued the explosive report, which sent shockwaves through the LGBTQ community as many called on David to resign.
David has denied any wrongdoing from the start, and the Human Rights Campaign board stood by him by announcing on the day the report was issued the organization had renewed his contract for another five years.
Internally, things are tense for David as the organization suffers from high turnover and the movement is under strain as anti-transgender bills advance through state legislatures and the Equality Act is held up in Congress. According to a report in the Huffington Post, a recording of a one-hour staff meeting between David and staff on Wednesday revealed a tense question as they asked him about his role in the Cuomo affair. One staffer asked, “When are you resigning?”
Another LGBTQ advocate included in the report is already making moves. Roberta Kaplan, who successfully argued in 2013 against the Defense of Marriage Act and has taken cases of women accusing former President Trump of sexual assault, has stepped down from her role as a board member for “Time’s Up,” according to reports in the Associated Press and New York Times.
(Kaplan was described in the report as having reviewed and read a potential op-ed seeking to discredit one of the survivors of sexual harassment to see if it was OK to make public. The op-ed went unpublished.)
The emails on Monday from the HRC board recognize the distress David’s inclusion in the report has caused the LGBTQ community. As noted in the email from the board and David, many people in the the LGBTQ community are survivors of sexual misconduct. Both emails, nonetheless, express a desire to continue forward.
“One thing we want to make clear, this investigation will in no way hinder the organization’s continued pursuit of the critical work necessary to being equity and liberation to the LGBTQ+ community,” the board writes in the email.
David in his email goes into detail about the findings in the report, maintaining he had no knowledge about any incident of sexual misconduct as described in the report and his inclusion in the report indicates no wrongdoing.
Although the report says David kept material from a personnel file on one of the accusers after he left Cuomo’s office and, after being asked by Cuomo for a copy, assisted in returning it to them in efforts to distribute it to the media and discredit the alleged victim, David says he was “legally obligated” to provide the report and “was not involved” in its public dissemination. Why he had the material in the first place is not addressed in his email. David is quoted in the report as saying that was because he was involved in counseling the employee.
Another component of report indicates David said he’d help seek out names for the op-ed that would have sought to discredit the accuser, although he allegedly said he wouldn’t sign the document. David, in his email, acknowledges he refused to sign it and says he “never agreed to circulate it.”
David, however, doesn’t in the email address a third component of the report finding he took part in discussions among Cuomo’s staffers about calling another accuser and secretly obtaining a recording in an attempt to discredit her. David told the Blade that was because his role in the conversation was in his capacity as legal counsel.
Although voices have emerged calling on David to resign, other LGBTQ leaders have come to David’s defense and others say they’re awaiting further information before rending a judgment.
Elizabeth Birch, a former executive director of the Human Rights Campaign, said in an email to the Washington Blade she stands behind David.
“I have enormous respect for Alphonso David,” Birch said. “No person who has endured sexual harassment should ever be silenced. I believe Alphonso when he states he did not participate in attempts to silence any of Governor Cuomo’s accusers.”
Meanwhile, the report is already hampering efforts to advance the legislative agenda for the LGBTQ movement and passage of the Equality Act, which was already all but dead in the U.S. Senate. Sen. Charles Grassley (R-Iowa) last week sent a letter to the Senate Judiciary Committee asking for inclusion of the AG report in the record, drawing on the ties between David and Cuomo’s sexual misconduct to build the narrative from opponents of the Equality Act asserting it would be a threat to women’s safety.
Kierra Johnson, executive director of the National LGBTQ Task Force, said in an email to the Washington Blade she is withholding judgment and her organization is “still processing the media related to the NY AG Cuomo investigation and report.”
“It is imperative, albeit at times difficult, that we remain vigilant in finding and accepting the truth and implementing interventions that facilitate our ability to rebuild trust and keep the work moving forward,” Johnson said. “These times require that we slow down, challenge ourselves to articulate and understand complexity and nuance, resist being reactive and lean into our values. We condemn sexual harassment and abuse, and we are in solidarity with the survivors’ quests for justice.”
Johnson, however added, the report makes clear Cuomo “should resign” because that would be “the right thing to do for NY and for survivors everywhere.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
